ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatitis C"

  • 2021 American Transplant Congress

    Comprehensive Utilization of HCV Viremic and Non-Viremic Donor Livers and Kidneys into HCV-negative Patients

    M. E. de Vera, J. Woloszyn, J. Sterris, M. Robinson, R. Evans, S. Blais, B. Elhazin, C. Amador, c. Berk, M. Volk, R. Villicana

    Transplant Institute, Loma Linda University Health, San Bernardino, CA

    *Purpose: We report our experience on virologic and graft outcomes of HCV-negative patients transplanted with HCV NAT+ (viremic) and HCV Ab+/NAT- (non-viremic) livers and kidneys…
  • 2021 American Transplant Congress

    Excellent Outcomes of Kidney Transplantation from Hepatitis C Infected Donors

    B. Rawashdeh, J. Dann, K. M. Marsh, A. Doddi, S. Rao, A. Agarwal

    UVA Health System, University of Virginia, Charlottesville, VA

    *Purpose: Utilization of Hepatitis C viremic (HCV D+) kidney donors in HCV naïve recipients has increased in the United States. While there are shorter waiting…
  • 2021 American Transplant Congress

    Association of Donor Hepatitis C Virus Infection Status and Risk of Bk Polyomavirus Viremia After Kidney Transplantation

    V. S. Potluri1, D. E. Schaubel1, M. E. Sise2, B. P. Concepcion3, R. C. Forbes1, E. A. Blumberg1, D. Goldberg4, P. P. Reese1, R. Bloom1, D. Shaffer3, R. Chung2, D. Sawinski1, I. Strohben2, N. Elias2, A. Azhar5, M. Shah1, J. Eason5, L. A. Binari3, M. Talwar5, V. Balaraman5, A. Bhalla5, B. Besharatian1, M. Z. Molnar5

    1University of Pennsylvania, Philadelphia, PA, 2Massachusetts General Hospital, Boston, MA, 3Vanderbilt University Medical Center, Nashville, TN, 4University of Miami Miller School of Medicine, Miami, FL, 5Methodist University Hospital, Memphis, TN

    *Purpose: Transplantation of kidneys from deceased donors with hepatitis C virus (HCV) infection into HCV-negative recipients has become more common, but some studies have suggested…
  • 2021 American Transplant Congress

    Alemtuzumab vs Antithymocyte Globulin Induction in Hepatitis C Viremic Donors to Hepatis C Negative Kidney Transplant Recipients

    K. Walter, L. Mincemoyer, J. Giang, J. Suero, N. Shah, K. Szempruch

    University of North Carolina Medical Center, Chapel Hill, NC

    *Purpose: The optimal induction agent for kidney transplantation of hepatitis C virus nucleic acid test positive donors to negative recipients (HCV NAT D+/R-) is unknown.…
  • 2021 American Transplant Congress

    Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants

    G. Gupta, I. Yakubu, P. Kimball, L. Kang, K. Mitchell, M. Shinbashi, D. Kumar, I. Moinuddin, L. Kamal, A. King, C. Bhati, M. Levy, A. Cotterell, A. Sharma, R. Sterling

    Virginia Commonwealth University Health System, Richmond, VA

    *Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
  • 2021 American Transplant Congress

    Improving Liver Transplantation Outcomes for Hepatitis C Associated Hepatocellular Carcinoma in Direct-Acting Antiviral Therapy Era

    K. Okumura, H. Sogawa, G. Veillette, D. John, T. Diflo, R. Bodin, D. C. Wolf, S. Nishida

    Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY

    *Purpose: Direct-acting antiviral (DAA) therapy has transformed the outcomes of liver transplantation(LT) in patients with hepatitis C virus (HCV). The aim of this study was…
  • 2021 American Transplant Congress

    Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants

    I. Yakubu, Y. Zhang, S. Ijioma, N. V. Carroll, J. Patterson, R. Sterling, G. Gupta

    Virginia Commonwealth University Health System, Richmond, VA

    *Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
  • 2021 American Transplant Congress

    Are Tacrolimus Concentrations Reduced with Direct-acting Antiviral Administration in Transplant Recipients?

    K. Huang, K. Farrow, M. Christian

    Pharmacy, Penn State Health Hershey Medical Center, Hershey, PA

    *Purpose: To evaluate the effects of direct-acting antivirals (DAAs) on tacrolimus trough concentrations and clinical outcome and to assess the need for a priori dose…
  • 2021 American Transplant Congress

    Outcomes of Kidney Transplantation from Hepatitis C Virus (HCV) Infected Donors Stratified by Recipient HCV Serostatus: A Mate Kidney Analysis

    K. K. Sureshkumar1, B. Chopra1, R. L. McGill2

    1Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA, 2Nephrology, University of Chicago, Chicago, IL

    *Purpose: Kidneys from donors infected with hepatitis C virus (HCV) are increasingly used for transplantation into HCV positive (+) recipients historically and into HCV negative…
  • 2021 American Transplant Congress

    Outcomes of Hepatitis C Nucleic Acid Testing Positive Donors in Aviremic Recipients With Delayed Direct-Acting Antiviral Initiation

    M. Hudson, A. Webb, A. Logan, A. Silverman, A. Brueckner

    Pharmacy, Tampa General Hospital, Tampa, FL

    *Purpose: The purpose of this study was to assess the clinical impact of utilizing hepatitis C virus (HCV) nucleic acid testing (NAT)+ donors in HCV…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 28
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences